Akero Therapeutics Inc Aktie News

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”). Akero investors have until June 25, 2024 to file a lead plaintiff motion. Investors ...

NEW ORLEANS , May 3, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company's shares between September 13, 2022 and October 9, 2023, inclusive (the "...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Akero investments or would li...

SAN DIEGO--(BUSINESS WIRE)---- $AKRO #AKRO--Robbins LLP Investigates Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding Viability and Efficacy of its Drug Candidate.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) investors concerning the Company's possible violations of federal securities laws. On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoin...

LOS ANGELES, CA / ACCESSWIRE / May 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investo...

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Akero business and prospects, resulting in its stock trading at inflated prices.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On October 10, 2023, Akero announced the results of its Phase 2b SYM...